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AbstrAct
Introduction Studies of the health effects of moist oral 
tobacco, snus, have produced inconsistent results. The 
main objective of this study is to examine the health 
effects of snus use on asthma, respiratory symptoms 
and sleep-related problems, a field that has not been 
investigated before.
Methods and material This cross-sectional study was 
based on a postal questionnaire completed by 26 697 
(59.3%) participants aged 16 to 75 years and living in 
Sweden. The questionnaire included questions on tobacco 
use, asthma, respiratory symptoms and sleeping problems. 
The association of snus use with asthma, respiratory 
symptoms and sleep-related symptoms was mainly tested 
in never-smokers (n=16 082).
Results The current use of snus in never-smokers was 
associated with an increased risk of asthma (OR 1.51 
(95% CI 1.28 to 1.77)), asthmatic symptoms, chronic 
bronchitis and chronic rhinosinusitis. This association 
was not present among ex-snus users. Snoring was 
independently related to both the former and current use 
of snus ((OR 1.37 (95% CI 1.12 to 1.68)) and (OR 1.59 
(95% CI 1.34 to 1.89), respectively)). A higher risk of 
difficulty inducing sleep was seen among snus users.
Conclusion Snus use was associated with a higher 
prevalence of asthma, respiratory symptoms and snoring. 
Healthcare professionals should be aware of these 
possible adverse effects of snus use.
InTroducTIon
Snus is a smokeless, moist tobacco product 
consisting mainly of tobacco, salt, water, 
humectants and flavouring.1 The tobacco 
in snus contains a number of harmful 
substances, including nicotine and tobac-
co-specific nitrosamines.2 In Sweden, where 
it is a very popular tobacco alternative, with 
18% men and 4% women being current users, 
snus is regulated under food legislation.3 4 
The highest proportion of snus users is found 
among men aged 40 years.5 In the mid-1990s, 
the prevalence of snus use among Swedish 
men surpassed the prevalence of smoking. 
The proportion of female snus users is rising, 
but it has still not reached the prevalence for 
women smokers.5 Compared with smoking, it 
has been suggested that the addiction to snus 
use is stronger, due to a lower cessation rate6 
and reports of greater experience of nicotine 
dependence,7 however, other data suggest 
that snus cessation may be less difficult than 
cigarette cessation.8 Some authors have 
suggested that snus is as a good alternative 
for smoking cessation due to the beneficial 
health effects compared with cigarettes.9
Studies aiming to identify the risk of health 
effects as a result of snus use have not reported 
consistent results. A significant increase in 
pancreatic cancer has been observed,10 11 but 
reports regarding the association between 
snus use and oral and pharyngeal cancer 
are inconclusive.10–12 Snus use appears to 
increase the risk of short-term case fatality 
after suffering from acute myocardial infarc-
tion13 and stroke.14 An increased risk of heart 
failure among snus users has been reported, 
with a particularly high risk of non-ischaemic 
heart failure among elderly men.15
There is only sparse evidence regarding the 
potential effect of snus on respiratory health 
and sleep. An association between snus and 
asthma has been reported in one study16 
and an elevated risk of insufficient sleep was 
found among smokeless tobacco users in 
Strengths and limitations of this study
 ► This is one of the first studies to investigate 
the  association between the use of snus and 
respiratory and sleep-related symptoms.
 ► The population is large which enables us to 
investigate subgroups such as never-smokers.
 ► Data are self-reported and some subjects may 
therefore be misclassified.
 ► The study is cross-sectional which makes it difficult 
to distinguish between causes and outcomes.
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another.17 The main objective of this paper was to investi-
gate the health effects of snus use on asthma, respiratory 
symptoms and sleep-related problems in a large general 
population sample.
MeThods
study design and participants
This cross-sectional study is based on observations from 
a postal questionnaire sent to 45 000 randomly selected 
subjects as part of the Global Allergy and Asthma Euro-
pean Network (GA2LEN) survey in 2008.18 In Sweden, 
26 697 (59.3%) participants responded. The subjects 
were aged 16 to 75 years and lived in four Swedish cities 
(Uppsala, Stockholm, Umeå and Gothenburg).16
Ethical approval was granted by the Regional Ethical 
Review Board in Uppsala, Sweden.
GA2Len questionnaire
The questionnaire included questions on respiratory 
symptoms, asthma and smoking. The questions also 
covered gender, age, weight and height. Body mass 
index (BMI) was calculated using the values of weight 
and height. In Sweden, the questionnaire also included 
questions on the use of snus and sleep-related symptoms. 
Listed below are definitions relevant to this paper.
Snus users were defined as those giving a positive answer 
to both the questions ‘Have you ever used snus every day 
for at least 6 months?’ and ‘Do you currently use snus?’.
Smokers were defined as those giving a positive answer 
to the questions ‘Have you ever smoked at least one ciga-
rette a day for at least 1 year?’ and ‘Have you smoked 
at all during the last month?’. Based on the answers to 
questions on snus use and smoking, the participants 
were divided into four groups: tobacco free, snus users, 
smokers and dual users.
Based on answers to the questions on snus use and 
smoking, the subjects were further divided into never-
snus, ex-snus and current snus users, as well as into 
never-smokers, ex-smokers and current smokers.
Asthma was defined as a positive answer to either of 
the questions ‘Have you had an asthma attack during 
the last 12 months?’ or ‘Are you currently taking 
any asthma medication including inhalers, sprays or 
tablets?’. Childhood asthma was defined as reporting 
having had an attack of asthma before the age of 13 
years.
Questions regarding asthmatic symptoms during the 
last 12 months included: (1) wheezing in the chest; (2) 
wheezing together with breathlessness; (3) wheezing 
without having a cold; (4) waking up with tightness in 
the chest; (5) waking up with shortness of breath and (6) 
waking up with a coughing attack.
Chronic bronchitis was defined as a positive answer to 
the question: ‘Are you used to having a cough almost 
every day with sputum production that lasts for at least 3 
months every year during the winter?’.
Allergic rhinitis was defined as a positive answer to the 
question ‘Have you had hay fever or a runny nose because 
of other allergies during the last 12 months?’.
Chronic rhinosinusitis was defined as suggested by the 
European Position Paper on Rhinosinusitis and Nasal 
Polyps (EP3OS) criteria 2007.19 It was considered to be 
present if participants stated that the following symptoms 
had been present for >12 weeks during the last 12 months: 
(1) nasal blockage, as well as one of the subsequent symp-
toms: (2) facial pain or pressure, (3) discoloured nasal 
discharge or (4) reduction or loss of smell. The disease 
was also considered to be present if both symptoms (2) 
and (3) were reported.
Sleep-related problems examined in this study were (1) 
snoring that is loud and interrupting, (2) difficulty 
inducing sleep (DIS), as in having a hard time falling 
asleep at night, (3) difficulty maintaining sleep (DMS), 
as in repeatedly waking up during the night, (4) being 
sleepy during the day (EDS) and (5) early morning awak-
ening (EMA), as in waking up too early and having a hard 
time falling asleep again.20 Each group included subjects 
who claimed they had the problem at least three to five 
times a week. The use of hypnotics was defined as a posi-
tive answer to the question ‘Do you take medication for 
sleeping problems?’.
Educational level was divided into three categories. (1) 
College was defined as having attended college/univer-
sity for >2½ years. (2) High school was defined as having 
attended high school or vocational school for >2 years. 
(3) Elementary school was defined as any education 
below the level of high school.
Activity level was divided into three categories depending 
on hours spent on intensive exercising per week. (1) 
Physically inactive was defined as zero hours a week. (2) 
Moderately physically active was defined as 0.5 to 3 hours 
a week. (3) Vigorously physically active was defined as 4 
to 7 hours a week.
data analysis
For statistical analyses, Stata V.12 was used. When 
comparing the characteristics of the study population, 
univariate analyses using the χ2 test were used. Multi-
variate logistic regression models were used to study 
independent associations between various symptoms and 
different groups of tobacco use after adjusting for poten-
tial confounders: gender, age, BMI, centre, educational 
level and physical activity. Subanalyses were performed 
in never-smokers and in never-smokers with reported 
asthma. Analyses of possible heterogeneity between the 
centres were performed using random effects meta-anal-
ysis. A p value of <0.05 was regarded as statistically 
significant.
resuLTs
The frequency of snus use among men was highest in 
the 25–35 age group. The number of snus-using women 
was highest in the 45–55 age group, with a steep decrease 
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thereafter. In overall terms, 18.0% of men and 4.7% of 
women in the study population used snus (figure 1).
In the whole population, snus use and dual use were 
highest in the 25–35 age group, whereas smoking was most 
prevalent at 55–65 years of age. The group of snus users 
had a higher BMI than the other groups. They were also 
more likely to be ex-smokers than persons in the tobac-
co-free group. Educational level and physical activity level 
were higher among snus users compared with smokers 
and dual users but lower compared with those who were 
tobacco free (table 1).
Tobacco use and symptoms
In table 2, we examined the association between tobacco 
use and symptoms after adjusting for likely confounders. 
Having asthma was independently related to using snus 
but not to smoking or the dual use of snus and cigarettes. 
Although the strongest associations with respiratory symp-
toms were found among smokers and dual users, snus users 
were more likely to suffer from wheezing and night-time 
chest tightness, as well as chronic bronchitis, allergic rhinitis 
and chronic rhinosinusitis, compared with the tobacco-free 
group. Snoring, DIS, EDS and the use of hypnotics were 
associated with all three groups of tobacco use. Snus users 
had a decreased risk of DMS (table 2). The corresponding 
unadjusted associations were fairly similar to the adjusted 
estimates (see online supplementary Table S1).
Figure 1 Proportion of men and women using snus among 
age groups.
Table 1 Characteristics of the study population (%)
Tobacco users
Tobacco 
free (n=20 699) Snus (n=2265) Smokers (n=3136)
Smokers and 
snus (n=597) p Value
Women 57.7 23.5 62.9 25.0 <0.001
Age (years) <0.001
  16–25 15.4 12.8 12.4 15.2
  25–35 21.4 23.2 17.4 26.7
  35–45 17.6 21.5 16.7 16.8
  45–55 15.4 19.7 20.0 21.5
  55–65 17.7 16.5 23.2 14.9
  >65 12.4 7.2 10.1 6.7
Body mass index <0.001
  <20 8.6 4.7 9.9 5.8
  20–25 51.9 46.6 48.9 48.1
  25–30 30.1 36.2 30.9 35.3
  >30 9.5 12.4 10.3 10.9
Ex-smokers 26.8 48.1 —- —— <0.001
Educational level <0.001
  Elementary school 15.0 12.5 23.6 18.6
  High school 31.6 42.9 40.7 45.8
  College 53.5 44.7 35.7 35.6
Activity level <0.001
  Physically inactive 18.1 19.3 32.8 27.8
  Moderately physically 
active
62.8 62.0 55.1 58.7
  Vigorously physically 
active
19.0 18.7 12.1 13.5
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snus use in never-smokers
In never-smokers, there was an association between snus 
use and asthma, all the asthmatic symptoms, chronic bron-
chitis and chronic rhinosinusitis. Sleeping problems with 
an increased risk among snus users were snoring and DIS. 
Also, among never-smokers, snus users had a decreased 
risk of DMS (table 3). The associations with asthma and 
nocturnal breathlessness became statistically non-signif-
icant when excluding subjects who have had attacks of 
asthma before the age of 13 years (n=1466) (adjusted 
OR (95% CI) 1.24 (0.89 to 1.71) and 1.32 (0.97 to 1.77), 
respectively). All the other association above remained 
statistically significant.
No significant heterogeneity between the centres 
was found between snus use and the health outcomes 
except for bronchitis where the association was partic-
ularly strong in Stockholm (adjusted OR (95% CI) 
2.35 (1.52 to 3.62)), whereas no significant association 
was found in Uppsala (OR 0.97 (0.60 to 1.57), pheteroge-
neity=0.04). The pooled estimates of the meta-analyses 
were very similar to those found in table 3 (data not 
shown). When snus users among asthma patients who 
had never smoked were examined, the only symptom 
with a significantly elevated risk was snoring (OR 2.68 
(1.58 to 4.55)).
history of snus use in never-smokers
Current snus use was an independent risk factor for 
having asthma, asthmatic symptoms, chronic bronchitis 
and chronic rhinosinusitis, while being an ex-snus user 
was not (table 4). Snoring was independently related to 
both the former and the current use of snus. A higher risk 
of DIS was seen among current snus users. Current snus 
users had a decreased risk of DMS, whereas ex-snus use 
was an independent risk factor for the problem. Being an 
ex-snus user was also an independent risk factor for EMA 
(table 4).
dIscussIon
Our results reveal a previously unknown association 
between snus use and negative health effects on the respi-
ratory tract. An increased risk of asthma, asthmatic and 
other respiratory symptoms was observed among snus 
users. An association between snus use and sleep-related 
problems was mixed with an increased risk of snoring and 
DIS but a decreased risk of DMS.
In the present study, 18% of men and 4.7% of women 
were using snus either exclusively or in combination 
with smoking. This is similar to the prevalence of snus 
use reported in a Swedish official statistics.4 According to 
our findings, snus use is proportionally higher in younger 
Table 2 The independent association between tobacco use and respiratory health and sleep-related symptoms (adjusted OR 
(95% CI))
Tobacco users
Snus users (n=2265) Smokers (n=3136)
Smokers and snus 
users (n=597)
Asthma 1.51 (1.28 to 1.77) 0.96 (0.82 to 1.13) 0.93 (0.65 to 1.33)
Asthmatic symptoms
  Wheezing 1.50 (1.33 to 1.69) 2.89 (2.64 to 3.17) 2.09 (1.71 to 2.55)
  Wheezing and breathlessness 1.42 (1.23 to 1.65) 2.11 (1.89 to 2.37) 1.46 (1.12 to 1.90)
  Wheezing without having a cold 1.50 (1.30 to 1.73) 2.67 (2.40 to 2.98) 2.17 (1.73 to 2.73)
  Night-time chest tightness 1.21 (1.05 to 1.40) 1.57 (1.40 to 1.75) 1.43 (1.12 to 1.82)
  Night-time attacks of breathlessness 1.02 (0.83 to 1.24) 1.44 (1.24 to 1.67) 1.58 (1.16 to 2.13)
  Night-time coughing 1.10 (0.99 to 1.23) 1.79 (1.64 to 1.94) 1.79 (1.49 to 2.15)
Chronic bronchitis 1.19 (1.03 to 1.37) 2.39 (2.16 to 2.65) 1.85 (1.48 to 2.31)
Allergic rhinitis 1.17 (1.05 to 1.30) 1.01 (0.91 to 1.11) 0.92 (0.75 to 1.13)
Chronic rhinosinusitis 1.28 (1.09 to 1.50) 1.78 (1.57 to 2.02) 1.78 (1.38 to 2.29)
Sleeping problems
  Snoring 1.41 (1.25 to 1.58) 1.78 (1.60 to 1.97) 2.16 (1.77 to 2.63)
  DIS 1.76 (1.56 to 1.99) 1.98 (1.79 to 2.19) 2.95 (2.43 to 3.58)
  DMS 0.74 (0.66 to 0.83) 0.97 (0.88 to 1.06) 0.91 (0.75 to 1.12)
  EDS 1.18 (1.07 to 1.31) 1.29 (1.19 to 1.41) 1.38 (1.16 to 1.65)
  EMA 0.87 (0.76 to 1.00) 1.14 (1.03 to 1.27) 0.91 (0.70 to 1.17)
  Use of hypnotics 1.33 (1.07 to 1.65) 2.08 (1.81 to 2.39) 2.77 (2.05 to 3.74)
Associations with a p value of <0.05 are marked as bold.
Adjusted for gender, age, BMI, centre, educational level and physical activity.
 BMI, body mass index; DIS, difficulty initiating sleep; DMS, difficulty maintaining sleep; EDS, excessive daytime sleepiness; EMA, early 
morning awakening at least three to five nights/week.
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age groups and among men than women, indicating an 
earlier initiation.
When compared with the tobacco-free group, a signif-
icant risk of asthma was observed among snus users but 
not among smokers and dual users. There is a possibility 
of reverse causation. Smoking is known to cause negative 
effects on asthma,21 the switch from smoking to snus use 
among asthmatic patients could possibly explain some of 
the associations between snus use and asthma. However, 
the fact that snus users who had never smoked also had an 
elevated risk of asthma and asthmatic symptoms excludes 
this possibility. This difference between snus users and 
smokers also raised concerns about whether asthmatic 
patients could be more prone to initiating snus use than 
cigarette smoking. Because the association with asthma 
and asthmatic symptoms was only present among current 
snus users but not ex-users of snus, this seems an unlikely 
explanation. We also found an association between snus 
use and respiratory symptoms when excluding partici-
pants who had childhood asthma. These findings suggest 
that snus causes an alteration in the lower respiratory tract, 
resulting in an increased likelihood of suffering from 
asthma and asthmatic symptoms. As asthmatic patients are 
a growing challenge among health professionals today,22 
these results deserve attention and further investigation. 
Similarly, to asthma and asthmatic symptoms, the risk of 
chronic bronchitis and chronic rhinosinusitis was only 
elevated among current snus users but not ex-snus users.
Current snus use was associated with snoring and, as 
the association remained present among ex-snus users, 
this suggests a partly irreversible effect from snus use on 
factors leading to snoring. Snoring is caused by high-fre-
quency oscillation of the soft palate, pharyngeal wall, 
epiglottis and tongue during sleep, due to the limited 
flow of air through the upper airways.23 The causes of 
limited airflow among patients who snore are diverse.24 25 
There are data indicating that, once snoring occurs, it 
causes progressive irreversible local neurogenic lesions, 
caused by the trauma of snoring.26 In former studies, 
hypnotics27 and alcohol consumption28 have been asso-
ciated with snoring. Adjustment for the use of hypnotics 
did not have any impact on the risk (results not shown), 
excluding it as an interfering factor in this study. However, 
we were not able to adjust for alcohol consumption, as 
the GA2LEN questionnaire did not include any questions 
about alcohol. It could thus serve as a confounder in our 
results. Obesity, gender, age and cigarette smoking are 
also possible confounders,27 all of which were adjusted 
for in our analyses.
In the group of snus users who had never smoked, 
being an asthma patient elevated the risk of snoring from 
1.53 to 2.68. This implies that being an asthmatic patient 
Table 3 Association between snus and respiratory health and sleep-related symptoms in never-smokers (%) and adjusted OR
Never smoked
Tobacco free
(n=14 914)
Snus users
(n=1168) p Value OR (95% CI)
Asthma 6.9 10.1 <0.001 1.49 (1.20 to 1.85)
Asthmatic symptoms
  Wheezing 12.9 18.8 <0.001 1.56 (1.32 to 1.84)
  Wheezing and breathlessness 8.2 10.9 0.002 1.38 (1.12 to 1.69)
  Wheezing without having a cold 8.0 11.8 <0.001 1.48 (1.21 to 1.80)
  Night-time chest tightness 9.4 12.0 0.004 1.41 (1.16 to 1.71)
  Night-time attacks of breathlessness 4.8 6.1 0.045 1.39 (1.07 to 1.82)
  Night-time coughing 23.1 23.1 0.987 1.27 (1.09 to 1.47)
Chronic bronchitis 9.0 12.5 <0.001 1.47 (1.21 to 1.78)
Allergic rhinitis 24.7 28.0 0.012 1.14 (0.99 to 1.31)
Chronic rhinosinusitis 7.1 9.3 0.005 1.37 (1.11 to 1.70)
Sleeping problems
  Snoring 11.7 19.0 <0.001 1.53 (1.29 to 1.82)
  DIS 11.1 16.5 <0.001 1.71 (1.44 to 2.03)
  DMS 25.3 15.8 <0.001 0.71 (0.59 to 0.84)
  EDS 28.7 29.8 0.433 1.08 (0.94 to 1.24)
  EMA 12.7 9.0 <0.001 0.83 (0.67 to 1.04)
  Use of hypnotics 4.0 3.1 0.143 1.24 (0.85 to 1.80)
Associations with a p value of <0.05 are marked as bold.
Adjusted for gender, age, BMI, centre, educational level and physical activity.
BMI, body mass index; DIS, difficulty inducing sleep; DMS, difficulty maintaining sleep; EDS, excessive daytime sleepiness; EMA, early 
morning awakening at least three to five nights/week.
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increases the sensitivity to possible effects of snus use 
contributing to snoring. Deterioration in health-related 
quality of life in asthmatic patients suffering from snoring 
has been reported.29 The possible prevention of snoring 
by reducing snus initiation among those suffering from 
asthma should therefore be prioritised.
The risk of DMS was found to be decreased among current 
snus users but increased among ex-snus users. Ex-snus users 
also ran an increased risk of EMA. These results suggest that 
snus use improves sleep and that a cessation leads to exacer-
bation. In spite of this, current snus users had an increased 
risk of DIS, but ex-snus users did not, which indicates mixed 
effects on the quality of sleep.
The biological explanation for the association between 
snus use and health outcomes in the present study is 
unknown. Gastro-oesophageal reflux is associated with 
smoking,30 respiratory symptoms and snoring,31 but the 
association between reflux and snus use is less clear.32 
Snus use was in one study found to be associated with an 
increased transfer factor for nitric oxide and a decrease 
in alveolar nitric oxide concentration indicating that snus 
may have an effect also on the lower airways.33
The main strength of this study is the use of a large 
database from a random general population sample. The 
response rate was lowest in Gothenburg (54.9%) and 
highest in Uppsala (59.1%).20 This response rate is some-
what lower than that previous epidemiological studies of the 
Swedish population have achieved,34 35 which is a limitation. 
In addition, the fact that this is a cross-sectional study makes 
it difficult to distinguish between causes and outcomes. A 
longitudinal study would be beneficial in order to indicate 
whether causation is present between snus use and these 
symptoms or only a connection. The fact that participants 
reported their history of snus use was, however, a great 
advantage, which helped us to draw conclusions about asso-
ciations. It would have been beneficial to include questions 
on the amount of snus used. We also lack data on alcohol 
consumption, which is a limitation as there are studies 
showing an association between use of snus and a higher 
use of alcohol.36 It is also possible that some of the associ-
ations between snus use and snoring are related to higher 
alcohol use in participants using snus.37 Another limita-
tion is the fact that the answers to the questionnaire are 
self-reported which might lead to underestimation or over-
estimation in some categories, especially those demanding 
more than a yes or no answer.16 It is, however, unlikely that 
the degree of underestimation or overestimation would 
differ between groups of tobacco use. We did not adjust for 
passive smoking, but we know from previous studies that 
the prevalence of passive smoking is very low in Sweden 
(<10%)38 so we do not think that this has influenced our 
results.
To the best of the authors’ knowledge, this field of effects 
has not been examined before. Further investigations will be 
needed to draw conclusions on possible reasons for limited 
airflow in the upper airways, an inflamed/mucus-secreting 
Table 4 Association between a history of snus use and respiratory health and sleep-related symptoms among never-smokers 
(adjusted OR (95% CI)
Ex-snus users (n=832) Snus users (n=1169)
Asthma 1.06 (0.79 to 1.40) 1.50 (1.21 to 1.86)
Asthmatic symptoms
  Wheezing 1.10 (0.89 to 1.36) 1.56 (1.32 to 1.84)
  Wheezing and breathlessness 1.00 (0.76 to 1.31) 1.37 (1.12 to 1.69)
  Wheezing without having a cold 1.24 (0.97 to 1.59) 1.51 (1.23 to 1.84)
  Night-time chest tightness 1.01 (0.78 to 1.30) 1.41 (1.16 to 1.71)
  Night-time attacks of breathlessness 1.27 (0.92 to 1.76) 1.42 (1.09 to 1.86)
  Night-time coughing 1.14 (0.96 to 1.37) 1.29 (1.11 to 1.50)
Chronic bronchitis 0.91 (0.70 to 1.19) 1.45 (1.20 to 1.76)
Allergic rhinitis 0.95 (0.80 to 1.12) 1.13 (0.98 to 1.30)
Chronic rhinosinusitis 0.95 (0.71 to 1.28) 1.36 (1.10 to 1.70)
Sleeping problems
  Snoring 1.37 (1.12 to 1.68) 1.59 (1.34 to 1.89)
  DIS 0.81 (0.62 to 1.05) 1.68 (1.41 to 2.00)
  DMS 1.20 (1.01 to 1.42) 0.72 (0.60 to 0.85)
  EDS 1.00 (0.85 to 1.18) 1.08 (0.94 to 1.24)
  EMA 1.28 (1.03 to 1.59) 0.85 (0.69 to 1.06)
  Use of hypnotics 1.32 (0.87 to 2.01) 1.26 (0.87 to 1.84)
Adjusted for gender, age, BMI, centre, educational level and physical activity.
BMI, body mass index; DIS, difficulty initiating sleep; DMS, difficulty maintaining sleep; EDS, excessive daytime sleepiness; EMA, early 
morning awakening at least three to five nights/week.
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respiratory tract and a mixed impact on the quality of 
sleep among snus users. Moreover, these results should be 
supported by further studies. Our results are important 
when considering tobacco control policies and can provide 
input to the discussion of whether snus is a good alternative 
for smoking cessation.
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